OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.
评价巴胺受体激动剂临床应疗效。
OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.
评价巴胺受体激动剂临床应疗效。
Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.
短期促腺激素释放因子治疗相关的副作用是常见的,但严重到足以停药的程度是罕见的。
Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.
罗匹尼罗是一种似多巴胺的多巴胺激动剂,与第一代多巴胺激动剂不同的是没有麦角林结构。罗匹尼罗的非麦角林结构可以说明其与多巴胺D2受体有较高的结合力。
声明:以上例句、词分
均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.
评价巴胺受体激动剂临床应疗效性。
Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.
短期促性腺激素释放因子治疗相关副作用是常见
,但严重到足以停药
程度是罕见
。
Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.
罗匹尼罗是一种类似多巴胺多巴胺激动剂,
第一代多巴胺激动剂不同
是没有麦角林结构。罗匹尼罗
非麦角林结构可以说明其
多巴胺D2受体有较高
结合力。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件观点;若发现问题,欢迎向我们指正。
OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.
评价巴胺受体激动临床应
性。
Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.
短期促性腺激素释放因子治的副作用是常见的,但严重到足以停药的程度是罕见的。
Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.
罗匹尼罗是一种类似多巴胺的多巴胺激动,与第一代多巴胺激动
不同的是没有麦角林结构。罗匹尼罗的非麦角林结构可以说明其与多巴胺D2受体有较高的结合力。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.
评价巴胺受激动剂临床应疗效性。
Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.
短期促性腺激释放因子治疗相关的副作用是常见的,但严重到足以停药的程度是罕见的。
Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.
罗匹尼罗是一种类似多巴胺的多巴胺激动剂,与第一代多巴胺激动剂不同的是没有麦角林结构。罗匹尼罗的非麦角林结构可以说明其与多巴胺D2受有较高的结合力。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.
评价巴胺受体激动剂临床应疗效。
Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.
短腺激素释放因子治疗相关
副作用
常见
,但严重到足以停药
程度
罕见
。
Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.
罗匹尼罗种类似多巴胺
多巴胺激动剂,与第
代多巴胺激动剂不同
没有麦角林结构。罗匹尼罗
非麦角林结构可以说明其与多巴胺D2受体有较高
结合力。
声明:以上例句、词分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件
观点;若发现问题,欢迎向我们指正。
OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.
评价巴胺受体激动剂临床应疗效性。
Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.
短期促性腺激释放因子治疗相关的副作用是常见的,但严重到足以停药的程度是罕见的。
Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.
罗匹尼罗是一种类似多巴胺的多巴胺激动剂,与第一代多巴胺激动剂不同的是没有麦角林结构。罗匹尼罗的非麦角林结构可以说明其与多巴胺D2受体有较高的结合力。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.
评价巴胺受体激动剂临床应疗效性。
Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.
短期促性腺激素释放因子治疗相关副作用是常见
,但严重到足以停
度是罕见
。
Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.
罗匹尼罗是一种类似多巴胺多巴胺激动剂,与第一代多巴胺激动剂不同
是没有麦角林结构。罗匹尼罗
非麦角林结构可以说明其与多巴胺D2受体有较高
结合力。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件观点;若发现问题,欢迎向我们指正。
OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.
评价巴胺受体动
临床应疗效
。
Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.
短期促素释放因子治疗相关
副作用是常见
,但严重到足以停药
程度是罕见
。
Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.
罗匹尼罗是一种类似多巴胺多巴胺
动
,与第一代多巴胺
动
不同
是没有麦角林结构。罗匹尼罗
非麦角林结构可以说明其与多巴胺D2受体有较高
结合力。
声明:以上例句、词分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件
观点;若发现问题,欢迎向我们
正。
OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.
评价巴胺受体激动剂临床应疗效性。
Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.
短期促性腺激素释放因子治疗相关的副作用是常见的,但严重到足以停的程度是罕见的。
Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.
罗匹尼罗是一种类似多巴胺的多巴胺激动剂,与第一代多巴胺激动剂不同的是没有麦角林结构。罗匹尼罗的非麦角林结构可以说明其与多巴胺D2受体有较高的结合力。
声明:以上、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。